SEARCH

SEARCH BY CITATION

References

  • 1
    Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanism and therapeutic opportunities. Eur J Cancer 2001; 37 ( Suppl 4): S3S8.
  • 2
    Olayioye M, Neve R, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 315967.
  • 3
    Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 216.
  • 4
    Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 15: 134352.
  • 5
    Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172187.
  • 6
    Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 2009; 158: 19.
  • 7
    Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 278799.
  • 8
    Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human murine monoclonal antibody. Drugs Today 2005; 41: 10727.
  • 9
    Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer 1997; 89: 3413.
  • 10
    Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenografts. Clin Cancer Res 2002; 8: 9941003.
  • 11
    Rougier P, Cunningham D, Nippgen J, Kohne CH. The CRYSTAL trial: efficacy and safety of irinotecan and 5-FU/FA with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25; 2531.
  • 12
    Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 140817.
  • 13
    Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 66371.
  • 14
    Bekaii-Saab T. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents. Clin Lung Cancer 2009; 10: 2308.
  • 15
    Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, et al. Kras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 175765.
  • 16
    Jean GW, Shah SR. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 2008; 28: 74254.
  • 17
    Ponz-Sarvisé M, Rodríguez J, Viudez A, Chopitea A, Calvo A, García-Foncillas J, Gil-Bazo I. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol 2007; 13: 587787.
  • 18
    Cascinu S, Berardi R, Salvagni S, Beretta GD, Catalano V, Pucci F, Sobrero A, Tagliaferri P, Labianca R, Scartozzi M, Crocicchio F, Mari E, et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 2008; 98: 716.
  • 19
    Ferris RL, Jaffee EM, Ferrone S. Tumor antigen–targeted, monoclonal antibody based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010; 28: 43909.
  • 20
    Correale P, Cusi MG, Tagliaferri P. Immune-modulatory properties of anticancer monoclonal antibodies. Is the “magic bullet” a still reliable paradigma? Immunotherapy 2011; 3: 14.
  • 21
    Wang SY, Weiner G. Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin Biol Ther 2008; 8: 75968.
  • 22
    Kawaguchi Y, Kono K, Mimura K, Sugai H, Akaike H, Fijii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2007; 120: 7817.
  • 23
    Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98: 127580.
  • 24
    Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WEIII., The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor-positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13: 641928.
  • 25
    Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13: 155261.
  • 26
    Hara M, Nakanishi H, Tsujimura K, Matsui M, Yatabe Y, Manabe T, Tatematsu M. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci 2008; 99: 14718.
  • 27
    Iannello A, Ahmad A. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487499.
  • 28
    Correale P, Marra M, Remondo C, Migali C, Misso G, Arcuri FP, Del Vecchio MT, Carducci A, Loiacono L, Tassone P, Abbruzzese A, Tagliaferri P, et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 2010; 46: 170311.
  • 29
    Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007; 12: 898910.
  • 30
    Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am 2006; 20: 585612.
  • 31
    Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J Exp Med 2002; 195: 16539.
  • 32
    Beum PV, Mack DA, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol 2008; 181: 812032.
  • 33
    Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, Imperatore V, Ciardiello F. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007; 26: 365460.
  • 34
    Correale P, Cusi MG, Del Vecchio MT, Aquino A, Prete SP, Tsang KY, Micheli L, Nencini C, La Placa M, Montagnani F, Terrosi C, Caraglia M, et al. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol 2005; 175: 8208.
  • 35
    Smithgall TE, Yu G, Glazer RI. Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukaemia cells as the product of the human c-fos locus and its expression in myelomonocytic cells. J Biol Chem 1988; 263: 150505.
  • 36
    Carter LL, Swain SL. Single cell analyses of cytokine production. Curr Opin Immunol 1997; 9: 17782.
  • 37
    Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, et al. 5-Fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 2005; 97: 143745.
  • 38
    Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87: 98290.
  • 39
    Correale P, Aquino A, Giuliani A, Pellegrini M, Micheli L, Cusi MG, Nencini C, Petrioli R, Prete SP, De Vecchis L, Turriziani M, Giorgi G, et al. Treatment of colon and breast carcinoma cells with 5-fluoruracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer 2003; 104: 437445.
  • 40
    Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 2008; 31: 13247.
  • 41
    Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol 2008; 181: 253343.
  • 42
    Callahan MK, Garg M, Srivastava PK. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proc Natl Acad Sci USA 2008; 105: 16627.
  • 43
    Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 11229.
  • 44
    Banerjee D, Matthews P, Matayeva E, Kaufman JL, Steinman RM, Dhodapkar KM. Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells. J Immunother 2008; 31: 11320.
  • 45
    Caraglia M, Marra M, Budillon A, Meo G, Ricciardiello F, Bismuto E, Brachelente G, Francini G, Giordano A, Correale P, Abbruzzese A. Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation. Cancer Biol Ther 2005; 4: 115967.
  • 46
    Casal J, Giménez MJ, Aguilar L, Yuste J, Jado I, Tarragó D, Fenoll A. β-Lactam activity against resistant pneumococcal strains is enhanced by the immune system. J Antimicrob Chemother 2002; 50 ( Suppl S2): 836.
  • 47
    Riccardi C, Bartocci A, Puccetti P, Spreafico F, Bonmassar E, Goldin A. Combined effects of antineoplastic agents and anti-lymphoma allograft reactions. Eur J Cancer 1980; 16: 2333.